Prucalopride

• Chronic Idiopathic Constipation
• Functional Constipation
• Colonic Motility Disorders

Prucalopride is a highly selective serotonin 5-HT4 receptor agonist used to treat chronic idiopathic constipation in adults whose symptoms have not improved adequately with over-the-counter laxatives. Unlike bulking agents, osmotic laxatives, or stimulant laxatives that work by drawing water into or irritating the bowel, prucalopride acts as a true prokinetic — it enhances the colon's intrinsic propulsive contractions, restoring more normal stool transit and bowel habit. It is part of the modern gastrointestinal toolkit for managing refractory functional bowel disorders and represents an important advance over earlier 5-HT4 agonists that were withdrawn for cardiovascular safety reasons.

Mechanism of Action

Serotonin (5-hydroxytryptamine) plays a central role in regulating gastrointestinal motility. About 95 percent of the body's serotonin resides in the gut, much of it stored in enterochromaffin cells in the intestinal mucosa, where it modulates motility, secretion, and visceral sensation through a family of receptor subtypes. The 5-HT4 receptor is widely expressed on enteric neurons and smooth muscle of the colon. When stimulated, it activates ascending excitatory pathways that contract smooth muscle proximal to a luminal stimulus and descending inhibitory pathways that relax muscle distal to it — the coordinated peristaltic reflex that propels content through the gut.

Prucalopride binds 5-HT4 receptors with high selectivity and affinity, increasing the frequency of high-amplitude propagating contractions in the colon. These large, organized contractions are responsible for moving fecal content from the right colon to the rectum and triggering the urge to defecate. Patients with chronic constipation often have a measurable deficit in HAPC frequency, and prucalopride directly addresses this. Critically, prucalopride has more than 150-fold selectivity for 5-HT4 over hERG potassium channels and other cardiac targets — the cross-reactivity that doomed earlier agents such as cisapride (which caused QT prolongation and ventricular arrhythmia) and tegaserod (which was associated with cardiovascular ischemic events). Prucalopride's clean cardiovascular safety profile across multiple large trials has been a major reason for its adoption.

Clinical Use

Procalopride is FDA-approved for chronic idiopathic constipation in adults, defined as constipation persisting more than 6 months without an identifiable secondary cause. American Gastroenterological Association and American College of Gastroenterology guidelines position it as a second-line agent after first-line measures: increased dietary fiber and fluid intake, polyethylene glycol or other osmotic laxatives, and stimulant laxatives such as bisacodyl or senna. Prucalopride is reserved for patients in whom these conventional approaches have produced inadequate symptom relief.

Alternatives in the prescription space include linaclotide and plecanatide, guanylate cyclase-C agonists that increase intestinal fluid secretion; and lubiprostone, a chloride channel activator. Choice among these depends on dominant symptoms (pure constipation vs. constipation with bloating or pain), tolerance of side effects (linaclotide and plecanatide commonly cause diarrhea; lubiprostone causes nausea), and insurance coverage. Prucalopride is particularly useful for patients with slow-transit constipation, those with prominent infrequent bowel movements rather than pain or bloating, and patients who have not tolerated the secretagogues. It is not approved for opioid-induced constipation, for which targeted antagonists are preferred. Pivotal trials demonstrated improved bowel frequency, reduced straining, improved stool consistency, and improved patient-reported quality of life over 12 weeks. Patient-facing information is available at medlineplus.gov.

How to Take It

The usual adult dose is 2 mg taken orally once daily, with or without food. The 1 mg tablet is reserved for patients with severe renal impairment (creatinine clearance below 30 mL/min) and as a starting dose in elderly patients with unknown renal function. The medication can be taken at any time of day, but consistent timing — for example, first thing in the morning — helps establish a routine and may align onset of effect with the body's natural morning gastrocolic reflex.

Most patients notice a first bowel movement within 1 to 4 days of initiation, with steady improvement in stool frequency and consistency over the following 2 weeks. Headache is the most common early side effect, often appearing in the first day or two and usually resolving within a week. Mild nausea, abdominal cramping, and increased flatulence are also common initially and typically subside as the gut adjusts to enhanced motility. If a dose is missed, take it as soon as remembered the same day; if it is nearly time for the next dose, skip the missed dose rather than doubling up. Store at room temperature in the original container. If symptoms have not improved after 4 weeks, the patient and clinician should reassess — continued use without benefit is not generally recommended.

Monitoring and Follow-Up

Before starting prucalopride, clinicians should confirm the diagnosis of chronic idiopathic constipation using Rome IV criteria and exclude alarm features such as unintentional weight loss, rectal bleeding, anemia, or new symptoms after age 50, which would prompt evaluation for structural disease. A complete medication review identifies constipating drugs that might be modified — opioids, anticholinergics, calcium channel blockers, iron, and aluminum-containing antacids are common contributors. Baseline renal function (creatinine, estimated GFR) guides dosing.

No routine laboratory monitoring is required during therapy. The most important follow-up is symptom-based: assessing bowel movement frequency, stool consistency on the Bristol stool scale, straining, sense of incomplete evacuation, and overall satisfaction. The American College of Gastroenterology recommends reassessment at 4 to 8 weeks. Mood should also be assessed at follow-up because uncommon but important reports have linked 5-HT4 agonists to depression and suicidal ideation; patients with prior mood disorders deserve closer surveillance. Renal function should be rechecked periodically in older patients or those on nephrotoxic medications. Persistent severe diarrhea, worsening abdominal pain, or signs of dehydration warrant dose reduction or discontinuation.

Special Populations

Elderly patients can use prucalopride safely, though slower titration starting at 1 mg daily is reasonable in those with reduced renal function or higher baseline cardiovascular risk. No dose adjustment is needed for mild to moderate hepatic impairment; severe hepatic impairment was not studied, so caution is warranted. Severe renal impairment requires the 1 mg dose. Pregnancy data are limited; animal studies showed no teratogenicity but the human experience is too small to establish safety, so use only when clearly needed. Prucalopride is excreted in breast milk in small amounts; the decision to breastfeed should weigh maternal need against unknown infant exposure, with most experts viewing short-term use as likely compatible.

Safety and efficacy have not been established in patients under 18, and the drug is not used in pediatrics. Patients with a history of arrhythmia or ischemic heart disease should still be approached with thoughtful assessment, even though prucalopride has a favorable cardiovascular profile compared with older 5-HT4 agonists. Prucalopride is contraindicated in patients with intestinal perforation or obstruction, severe inflammatory bowel disease, or toxic megacolon.

When to Contact Your Doctor

Seek emergency care for severe abdominal pain, persistent vomiting, abdominal distension with inability to pass gas or stool (possible obstruction), rectal bleeding beyond a few drops on the toilet paper, severe diarrhea with signs of dehydration such as lightheadedness or reduced urination, or fainting. New or worsening depression, persistent low mood, or any thoughts of self-harm should be reported immediately — the FDA labeling warns of these uncommon but serious adverse effects. Palpitations, chest discomfort, or new shortness of breath warrant evaluation, particularly in patients with underlying cardiovascular disease.

Sudden severe headache that differs from prior headaches, new neurologic symptoms, or signs of allergic reaction such as facial swelling, hives, or difficulty breathing should prompt urgent care. If diarrhea becomes severe enough to cause significant fluid loss or interfere with daily activities, contact your clinician for guidance on temporary dose reduction or pause.

Patients who develop new urinary retention, severe back pain, or any neurologic symptoms in the lower extremities should be evaluated promptly to exclude unrelated but important conditions that can present with bowel changes. Persistent fatigue, ongoing weight loss, or progressive abdominal distension that does not improve with prokinetic therapy may suggest a process beyond functional constipation — such as a structural lesion, motility disorder requiring specialist evaluation, or systemic disease — and warrants reassessment by a gastroenterologist. The American College of Gastroenterology and the International Foundation for Gastrointestinal Disorders provide additional educational resources for patients living with chronic bowel disorders.

For evaluation of chronic constipation that has not responded to standard measures and consideration of prokinetic options such as prucalopride, contact us or schedule a visit with the Zimmer Medical Group team for personalized care.